Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum:: a meta-analysis -: art. no. 28

被引:141
作者
González-Pérez, A [1 ]
Rodríguez, LAG
López-Ridaura, R
机构
[1] Ctr Espanol Invest Farmacoepidemiol, Madrid, Spain
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
关键词
D O I
10.1186/1471-2407-3-28
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Observational studies have consistently shown that aspirin and non-steroidal anti-inflammatory drug (NSAID) use is associated with a close to 50% reduced risk of colorectal cancer. Studies assessing the effects of NSAIDs on other cancers have shown conflicting results. Therefore, we conducted a meta-analysis to evaluate the relationship between NSAID use and cancer other than colorectal. Methods: We performed a search in Medline (from 1966 to 2002) and identified a total of 47 articles (13 cohort and 34 case-control studies). Overall estimates of the relative risk (RR) were calculated for each cancer site using random effects models. Results: Aspirin use was associated with a reduced risk of cancer of the esophagus and the stomach (RR, 0.51; 95% CI (0.38-0.69), and 0.73; 95% CI (0.63-0.84)). Use of NSAIDs was similarly associated with a lower risk of esophageal and gastric cancers (RR, 0.65; 95% CI(0.46-0.92) and RR, 0.54; 95% CI (0.39-0.75)). Among other cancers, only the results obtained for breast cancer were fairly consistent in showing a slight reduced risk among NSAID and aspirin users (RR, 0.77; 95% CI (0.66-0.88), and RR, 0.77; 95% CI (0.69-0.86) respectively)). Conclusions: The results of this meta-analysis show that the potential chemopreventive role of NSAIDs in colorectal cancer might be extended to other gastrointestinal cancers such as esophagus and stomach. Further research is required to evaluate the role of NSAIDs at other cancers sites.
引用
收藏
页数:12
相关论文
共 82 条
[1]   Aspirin and lung cancer in women [J].
Akhmedkhanov, A ;
Toniolo, P ;
Zeleniuch-Jacquotte, A ;
Koenig, KL ;
Shore, RE .
BRITISH JOURNAL OF CANCER, 2002, 87 (01) :49-53
[2]   Aspirin and epithelial ovarian cancer [J].
Akhmedkhanov, A ;
Toniolo, P ;
Zeleniuch-Jacquotte, A ;
Kato, I ;
Koenig, KL ;
Shore, RE .
PREVENTIVE MEDICINE, 2001, 33 (06) :682-687
[3]   Aspirin and risk for gastric cancer:: a population-based case-control study in Sweden [J].
Akre, K ;
Ekström, AM ;
Signorello, LB ;
Hansson, LE ;
Nyrén, O .
BRITISH JOURNAL OF CANCER, 2001, 84 (07) :965-968
[4]  
Anderson KE, 2002, J NATL CANCER I, V94, P1168, DOI 10.1093/jnci/94.15.1168
[5]   The role of cyclooxygenase inhibitors in cancer prevention [J].
Anderson, WF ;
Umar, A ;
Viner, JL ;
Hawk, ET .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (12) :1035-1062
[6]   Nonsteroidal anti-inflammatory drugs and cancer prevention [J].
Baron, JA ;
Sandler, RS .
ANNUAL REVIEW OF MEDICINE, 2000, 51 :511-523
[7]   NSAIDs and a lower risk of prostate cancer: Causation or confounding? [J].
Barry, MJ .
MAYO CLINIC PROCEEDINGS, 2002, 77 (03) :217-218
[8]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[9]  
Bucher C, 1999, CLIN NEPHROL, V51, P67
[10]  
Castelao JE, 2000, BRIT J CANCER, V82, P1364